Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Blood (2019) 134 (Supplement_1): 1582.
Currently there are no citedby results. Try again later.
